Abbott Laboratories (ABT) Hisse Özeti
Abbott Laboratories, iştirakleri ile birlikte dünya çapında sağlık bakım ürünleri keşfeder, geliştirir, üretir ve satar. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 1/6 |
| Gelecekteki Büyüme | 2/6 |
| Geçmiş Performans | 2/6 |
| Finansal Sağlık | 3/6 |
| Temettüler | 5/6 |
ABT Community Fair Values
Create NarrativeSee what 317 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Abbott Laboratories
10.4% değerinin altında içsel indirim
ABT Market Outlook
View narrativeNA
Published 4 Jan 2025
Abbott Laboratories Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$102.03 |
| 52 Haftanın En Yüksek Seviyesi | US$137.49 |
| 52 Haftanın En Düşük Seviyesi | US$81.97 |
| Beta | 0.59 |
| 1 Aylık Değişim | -8.29% |
| 3 Aylık Değişim | 15.29% |
| 1 Yıllık Değişim | -23.15% |
| 3 Yıllık Değişim | 1.35% |
| 5 Yıllık Değişim | -18.46% |
| Halka arzdan bu yana değişim | 27,760.99% |
Son Haberler & Güncellemeler
Recent updates
Seeking Alpha • Aug 19
Abbott Laboratories: Reasonably Valued After Surge, But Still An Attractive Buy Long-Term
Summary Abbott Laboratories remains a buy, with accelerating earnings growth, margin expansion, and robust segment performance following Q2’s double beat and guidance raise. ABT’s Exact Sciences acquisition strengthens its long-term growth runway, supporting a raised EPS outlook and 10.4% CAGR over the next six years. Despite recent price appreciation, ABT trades below its 5-year forward P/E average, offering a 2.5% yield and a potential 37% upside to a $151 price target. Risks include Nutrition segment volatility, regulatory scrutiny on the pipeline, and international exposure, but ABT’s A credit rating and Dividend King status support a premium valuation. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Jul 23
ABT: Cancer Diagnostics Expansion And Dividend Streak Will Drive Future Repricing
Abbott Laboratories' fair value estimate has moved from $116.54 to $119.13. This reflects analysts' higher price targets in the $112 to $121 range after Q2 results that were viewed as better than expected and supported by updated models and confidence in longer term growth drivers.Analiz Makalesi • Jun 21
Abbott Laboratories (ABT) Stock Could Be 24% Below Fair Value Before Earnings
Dividend affirmation and earnings catalyst put Abbott Laboratories stock in focus Recent commentary on Abbott Laboratories (ABT) has centered on upcoming earnings and Citi highlighting the value of its diversified healthcare businesses, setting the stage for closer attention to the stock. The reaffirmed quarterly dividend and the approaching July 16 earnings report give investors timely reference points as they weigh Abbott Laboratories stock, its current business mix, and expectations around...Anlatı Güncellemesi • Jun 16
ABT: Cancer Diagnostics Expansion And Dividend Streak Will Support Future Repricing
Analysts have nudged their fair value estimate for Abbott Laboratories slightly lower from about $117.29 to $116.54, reflecting a series of reduced Street price targets that cite utilization and inflation headwinds, while still applying a modestly lower discount rate and a slightly softer future P/E assumption. Analyst Commentary Recent Street research on Abbott Laboratories points to a more cautious tone, with many price targets cut and utilization and inflation flagged as key issues.Anlatı Güncellemesi • Jun 02
ABT: Cancer Diagnostics Expansion And Dividend Streak Will Support Future Repricing
Analysts have nudged their fair value estimate for Abbott Laboratories slightly lower to about $117.29 from $118.64. This reflects a series of reduced price targets and more cautious outlooks on growth and valuation across recent research updates.Anlatı Güncellemesi • May 12
ABT: Medtech Pipeline And Dividend Record Will Support Future Repricing
Analysts have trimmed Abbott Laboratories' consolidated price target by $1, reflecting a slightly higher discount rate, a marginally lower revenue growth outlook, a very small adjustment to profit margin assumptions, and a modestly lower future P/E multiple in light of several recent target cuts and a removal from a conviction list. Analyst Commentary Recent Street research on Abbott Laboratories has tilted more cautious, with a series of price target reductions and a removal from a major conviction list.Anlatı Güncellemesi • Apr 23
ABT: AF Portfolio And Dividend Track Record Will Support Future Repricing
Analysts have trimmed Abbott Laboratories' implied fair value estimate to $118.64 from $131.44. This reflects a series of recent price target reductions as they factor in updated growth, margin and P/E assumptions.Anlatı Güncellemesi • Apr 09
ABT: AF Portfolio And Dividend Track Record Will Support Future Upside
Abbott Laboratories' updated analyst price target reflects a modest reset, with fair value moving from $132.64 to $131.44 as analysts factor in higher assumed revenue growth of 10.24%, a lower profit margin of 15.60% and a slightly richer future P/E of 30.91x. Analyst Commentary Recent research on Abbott Laboratories points to an active debate around how much investors should pay for the stock, with several price target changes clustered over the past few months.Anlatı Güncellemesi • Mar 26
ABT: AF Portfolio Advancements And Dividend Streak Will Support Future Upside
Analysts have trimmed Abbott Laboratories' fair value estimate by about $0.70 to $132.64. This reflects a series of recent target cuts across the Street, even as they continue to reference generally healthy medtech sector fundamentals.Anlatı Güncellemesi • Mar 11
ABT: AF Portfolio Progress And Dividend Streak Will Drive Future Upside
Analysts have trimmed their average price targets on Abbott Laboratories by a few dollars, reflecting slightly higher required returns and refreshed assumptions on fair value, while still grounding their views in recent research that includes both target cuts and at least one upward revision. Analyst Commentary Recent research on Abbott Laboratories gives you a mixed but useful read on how the Street is thinking about valuation, execution, and growth.Anlatı Güncellemesi • Feb 24
ABT: Exact Sciences Deal And AF Portfolio Will Reshape Future Upside
Analyst targets on Abbott Laboratories have moved lower by double digit dollar amounts, with multiple firms trimming their price objectives in U.S. dollars as they factor in updated assumptions on discount rates, long term revenue growth, margins and future P/E expectations. Analyst Commentary Recent Street research on Abbott Laboratories reflects a mix of caution on valuation and optimism around the company’s longer term positioning, with several firms resetting price targets and one firm upgrading the stock.Anlatı Güncellemesi • Feb 10
ABT: Exact Sciences Deal Will Reshape Testing Franchise And Future Upside
Analysts have trimmed their fair value estimate for Abbott Laboratories by about $3 to roughly $133. This reflects modestly softer revenue growth assumptions, a slightly lower future P/E multiple near 30x, and recent reductions in price targets across several firms, even as some still highlight the pending Exact Sciences deal as a key part of their thesis.Anlatı Güncellemesi • Jan 26
ABT: Exact Sciences Acquisition Will Shape Future Earnings Mix And Upside Potential
Analysts have reduced their fair value estimate for Abbott Laboratories by about $8 to $136.47, reflecting a series of recent price target cuts that incorporate slightly adjusted growth, discount rate and P/E assumptions, along with expectations for a modestly higher profit margin profile. Analyst Commentary Recent research updates show a mix of optimism and caution around Abbott Laboratories, with several firms adjusting price targets and factoring in the pending Exact Sciences acquisition.Anlatı Güncellemesi • Jan 11
ABT: Exact Sciences Deal And Legal Wins Will Support Future Upside
Narrative Update Overview The updated analyst work on Abbott Laboratories reflects a small increase in the implied fair value to about $144.75. Analysts point to a tighter discount rate, steady growth and margin assumptions, and a blended view of recent price target changes that factor in medical devices momentum, the pending Exact Sciences deal, and reduced legal overhangs.Analiz Makalesi • Jan 03
Returns On Capital Are Showing Encouraging Signs At Abbott Laboratories (NYSE:ABT)
What are the early trends we should look for to identify a stock that could multiply in value over the long term? One...Anlatı Güncellemesi • Dec 27
ABT: Exact Sciences Deal And Legal Wins Will Drive Future Returns
Analysts modestly raised their average price target for Abbott Laboratories to about $144 per share, citing resilient mid-single digit organic revenue growth, double digit earnings power supported by a diversified healthcare portfolio, accelerating momentum in Medical Devices despite some near term lumpiness, and potential strategic upside from the pending Exact Sciences acquisition at a premium takeout valuation. Analyst Commentary Street research remains broadly constructive on Abbott, with recent notes highlighting both upside drivers and areas of near term scrutiny as investors digest the Exact Sciences transaction and mixed quarterly optics.Anlatı Güncellemesi • Dec 12
ABT: Exact Sciences Deal And Legal Wins Will Drive Future Upside
Analysts made a modest adjustment to their Abbott Laboratories price targets, with estimates moving in a roughly $2 range around the mid-$140s as they balanced optimism around the pending Exact Sciences acquisition, resilient device driven growth, and favorable legal developments against some near term lumpiness in non device segments. Analyst Commentary Research coverage around Abbott remains largely constructive, with most views anchored on a durable devices growth profile, incremental benefits from the proposed Exact Sciences transaction, and diminishing legal overhangs.Anlatı Güncellemesi • Nov 28
ABT: Exact Sciences Acquisition And Legal Wins Will Drive Medium-Term Upside
Abbott Laboratories’ analyst price target saw a modest decrease to $144.43 as analysts point to shifting expectations around profit margin and a slightly higher discount rate. This development is tempered by optimism for ongoing revenue growth and stability in core medical device performance.Anlatı Güncellemesi • Nov 14
ABT: Momentum From Legal Win And Product Approvals Will Support Future Gains
Analysts have modestly revised their price targets for Abbott Laboratories, with recent updates ranging from $142 to $146 per share. They cite strong momentum in Medical Devices and a resilient, diversified business model, despite varied performance across business segments.Analiz Makalesi • Nov 05
Abbott Laboratories' (NYSE:ABT) Earnings Are Weaker Than They Seem
Abbott Laboratories ( NYSE:ABT ) announced strong profits, but the stock was stagnant. Our analysis suggests that...Anlatı Güncellemesi • Oct 31
ABT: Legal Wins And Device Momentum Will Support Durable Growth Ahead
Abbott Laboratories' average analyst price target experienced a modest increase to approximately $144.47. Analysts cited positive legal developments and continued momentum in the Medical Devices segment as key factors supporting the adjustment.Anlatı Güncellemesi • Oct 16
Expanding Emerging Markets And Diagnostics Will Drive Prospects Despite Headwinds
Analysts have modestly increased their price target for Abbott Laboratories from $142.48 to $144.40, citing resilient growth in medical devices and expectations for steady double-digit earnings growth, even though there may be some near-term variability across business segments. Analyst Commentary Recent research notes reflect a mix of optimism and caution from analysts following Abbott Laboratories' latest results and updates to price targets.Hissedar Getirileri
| ABT | US Medical Equipment | US Pazar | |
|---|---|---|---|
| 7D | -3.3% | -0.4% | -1.6% |
| 1Y | -23.1% | -16.3% | 12.1% |
Getiri vs. Endüstri: ABT geçen yıl % -16.3 oranında getiri sağlayan US Medical Equipment sektörünün gerisinde kaldı.
Getiri vs Piyasa: ABT geçen yıl % 12.1 oranında getiri sağlayan US Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| ABT volatility | |
|---|---|
| ABT Average Weekly Movement | 4.6% |
| Medical Equipment Industry Average Movement | 8.1% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.2% |
| 10% least volatile stocks in US Market | 2.9% |
İstikrarlı Hisse Senedi Fiyatı: ABT son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: ABT 'nin haftalık oynaklığı ( 5% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1888 | 115,000 | Robert Ford | www.abbott.com |
Abbott Laboratories, iştirakleri ile birlikte dünya çapında sağlık bakım ürünleri keşfeder, geliştirir, üretir ve satar. Dört segmentte faaliyet göstermektedir: Yerleşik Farmasötik Ürünler, Teşhis Ürünleri, Beslenme Ürünleri ve Tıbbi Cihazlar. Şirket, pankreatik ekzokrin yetmezliği, irritabl bağırsak sendromu veya biliyer spazm, intrahepatik kolestaz veya depresif semptomlar, jinekolojik bozukluk, hormon replasman tedavisi, dislipidemi tedavisi için jenerik ilaçlar sunmaktadır, hipertansiyon, hipotiroidizm, hipertrigliseridemi, Ménière hastalığı ve vestibüler vertigo, ağrı, ateş, enflamasyon ve migrenin yanı sıra anti-enfektif klaritromisin, influenza aşısı ve kolonun fizyolojik ritmini düzenleyen ürünler sunmaktadır.
Abbott Laboratories Temel Bilgiler Özeti
| ABT temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$178.39b |
| Kazançlar(TTM) | US$5.40b |
| Gelir(TTM) | US$46.59b |
32.7x
F/K Oranı3.8x
P/S OranıABT aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| ABT gelir tablosu (TTM) | |
|---|---|
| Gelir | US$46.59b |
| Gelir Maliyeti | US$20.10b |
| Brüt Kâr | US$26.48b |
| Diğer Giderler | US$21.08b |
| Kazançlar | US$5.40b |
Son Raporlanan Kazançlar
Jun 30, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | 3.12 |
| Brüt Marj | 56.85% |
| Net Kâr Marjı | 11.59% |
| Borç/Özkaynak Oranı | 63.2% |
ABT uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünTemettüler
2.5%
Mevcut Temettü Verimi80%
Ödeme OranıŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/09/15 04:06 |
| Gün Sonu Hisse Fiyatı | 2026/09/15 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Abbott Laboratories 47 Bu analistlerden 27, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| David Toung | Argus Research Company |
| David Rescott | Baird |
| Matthew Miksic | Barclays |